Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.

ABSTRACT: Immune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor-mediated colitis (IMC) is a significant complication from ICI and can have life-threatening consequences. Based on clinical presentation, IMC mimics inflammatory bowel disease, however the link is poorly understood. We hypothesized that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) may predispose to IMC. We developed and validated polygenic risk scores for CD (PRS_CD) and UC (PRS_UC) in cancer-free individuals and assessed the role of each of the

SUBMITTER: Middha P 

PROVIDER: S-EPMC10246037 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature